fashion -WSS

fashion

author：Wikipedia 2025-10-02 07:25:07 - browse：18198

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

knowledge

WSS

My superpower is killing ticks

Why 40% Americans with Parkinson’s don’t see a neurologist

HCA discloses massive data breach affecting 11 million patients

Verily hires former Apple Health leader as chief scientific officer

Dramatically reducing cancer deaths requires the PASTEUR Act

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

knowledge

fashion

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Duchenne breakthrough therapy leaves behind pioneering families

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Affirmative action in medical school literally saved lives

Humana, CVS hope to turn members into patients at clinics

Medicare details structure of new drug price negotiation program

Stem cell clinics for heart failure: buyer be wary

Psychedelics group wrestles with new pharma identity

'Ancient DNA,' 23andMe reveal African American ancestries

focus

Petition to FDA: Get the lead out of consumer hair dyes

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Bulgari apologizes to China for listing Taiwan as a country after online backlash

California’s proposed $25 per hour health care minimum wage

The drug industry sees a key ally in the Senate prevail

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

knowledge

explore

leisure time

leisure time